The study results showed that 33.9% Otezla patients achieved MDA-Joints response vs 16.0% in PBO and 70.2% Otezla patients achieved clinical disease activity in psoriatic arthritis (cDAPSA) remission or low disease activity (LDA >4 to ≤13) vs 51.8% in PBO. The results will be presented at ACR’23
The PBO-controlled, multicenter, randomized, double-blind, parallel-group P-IV (FOREMOST) study is to evaluate patients (n=308) for the treatment of oligoarticular psoriatic arthritis with early disease duration of 5 or fewer years
Otezla (apremilast) is an oral medication that selectively inhibits phosphodiesterase 4 (PDE4), a small-molecule enzyme, with a specific focus on c (cAMP)
Ref: Amgen | Image: Amgen
Related News:- Amgen Announces Positive Top-Line Results of Otezla (apremilast) from P-III (DISCREET Study) to Treat Genital Psoriasis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
